HB THERAPEUTICS INC

HB Therapeutics Inc is an early-stage biotech company based in Indianapolis, Indiana focused on the discovery and development of small molecule degraders that induce ubiquitination and degradation of oncoproteins. The company's lead program targets small ubiquitin-like modifier-1 protein (SUMO1) as a new anticancer drug for the treatment of glioblastoma. HB Therapeutics received an NIH/NCI SBIR Phase I grant of $300,000 for development of its first SUMO1 small molecule degraders and is housed at the Indiana Center for Biomedical Innovation.